Limiting the analysis to the subset of patients with lung adenocarcinoma (LAC) resulted in greater hazard ratios relating PRSS3 expression with poor OS (HR 2.22, P = 9e-12; Fig. 1c) and poor PFS (HR 2.26, P = 2.7e-7; Fig. 1d). Here, PRSS3 is linked to lung adenocarcinoma.